Glucarpidase - BTG

Drug Profile

Glucarpidase - BTG

Alternative Names: Carboxypeptidase G2; CPG2; OP 07; OP-07 - Ohara Pharmaceuticals; Voraxaze

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Health Protection Agency Porton Down
  • Developer BTG; Ohara Pharmaceutical
  • Class Carboxypeptidases
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chemotherapy-induced damage
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced damage

Most Recent Events

  • 09 Jan 2017 Phase-II clinical trials in Chemotherapy induced damage in Japan (IV) (Ohara Pharmaceuticals pipeline, January 2017)
  • 09 Jan 2017 Phase-II clinical trials in Chemotherapy induced damage in Japan (IV) before January 2017 (Ohara Pharmaceuticals pipeline, January 2017)
  • 04 Jun 2012 Efficacy and adverse events data from a clinical trial in Chemotherapy induced damage/Chemoprotection released by BTG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top